Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
Change Password
For better security, update the account password.
Title/Summary: Tender for non-exclusive discount agreements for the drug Aflibercept under an Open-House model issued by AOK PLUS – The Health Insurance Fund for Saxony and Thuringia, located in Erfurt, Germany. The tender is open for submissions until December 31, 2027.
Scope Of Work: This tender involves establishing non-exclusive discount agreements for the drug Aflibercept as an injection solution, under the Open-House model. Participation is open to all interested pharmaceutical companies that meet the requirements. The quantity of drug required is uncertain, depending on demand and other factors. Interested parties must apply for access to the project room on the German Procurement Portal (DTVP) to obtain participation documents, which must be kept confidential. The agreements will not guarantee minimum order quantities and will end by December 31, 2027, unless terminated earlier.
Qualification Criterion: Eligible bidders must be pharmaceutical companies that comply with the participation requirements outlined in the project documents available on the DTVP. They must submit a request for access to the project room and adhere to confidentiality regarding the content of the participation documents. All submitted materials must be destroyed if participation is declined. The tender requires electronic communication and document submission through the DTVP portal. Late submissions will be considered at the next deadline.
Purchaser contact is for registered users
Login to see detailsTender details are for registered users
Login to see details| Tender | Country | TOT Ref. No. | Bid deadline |
|---|---|---|---|
| Operation of a Dynamic Procurement System for Laboratory Consumables. | Germany | 152653979 | 02 Jan 2027 |
| Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V with the Active Ingredient Ustekinumab from January 1, 2027 | Germany | 152653877 | 10 Aug 2028 |
| Open House Biologics Discount Agreements 2026-09 - Etanercept | Germany | 152653671 | 31 Dec 2026 |
| Delivery of Cleaning Products, Anker Facilities, Gu Etc., Government of Lower Bavaria | Germany | 152653374 | 17 Dec 2026 |
| Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Tacrolimus (Atc: D11ah01). | Germany | 152653349 | 27 Oct 2028 |